Managing the Surge: How Health Systems Are Tackling Rising Specialty Drug Costs
The cost of specialty medications is no longer just a budgetary concern; it’s a systemic crisis. As new gene therapies and complex biologics enter the market, health systems are struggling to balance patient access with financial sustainability. At the recent Asembia Specialty Pharmacy Summit, pharmacy leaders from the Mayo Clinic and other top institutions highlighted a critical shift in strategy: moving away from reactive purchasing toward an integrated, value-based management model.
Specialty drugs—defined as high-cost medications used to treat complex, chronic, or rare conditions—now account for a disproportionate share of total drug spend despite being used by a small percentage of the patient population. To survive this trend, health systems are reimagining the role of the specialty pharmacy within the continuum of care.
The Drivers of Rising Specialty Spend
Several factors are converging to drive costs upward. The primary driver is the rapid development of FDA-approved orphan drugs and cell and gene therapies, which often carry price tags in the hundreds of thousands, or even millions, of dollars per dose. The expansion of chronic disease indications for existing biologics means more patients are qualifying for these expensive treatments.
Beyond the sticker price, health systems face administrative burdens. The complexity of prior authorizations and the fragmented nature of payer reimbursement often lead to delays in treatment, which can result in worse patient outcomes and higher long-term costs due to emergency interventions.
Strategic Shifts in Pharmacy Management
Pharmacy leaders are implementing several key strategies to mitigate these costs while maintaining high standards of care.
Site-of-Care Optimization
One of the most effective ways to reduce spend is shifting the administration of drugs from high-cost hospital outpatient departments to more cost-effective settings, such as physician offices or the patient’s home. This transition not only lowers the facility fee but often improves the patient experience by reducing travel and wait times.
Integrated Clinical Pharmacy Models
Rather than treating the pharmacy as a separate dispensing entity, leading health systems are integrating pharmacists directly into the clinical care team. When pharmacists collaborate with prescribing physicians in real-time, they can identify more affordable therapeutic alternatives or ensure that the most expensive drug is reserved for patients who truly need it.
Data-Driven Utilization Management
Health systems are increasingly using advanced analytics to track medication adherence and outcomes. By monitoring how patients respond to expensive therapies, systems can discontinue ineffective treatments sooner, preventing wasteful spending on drugs that aren’t providing clinical value.
“The goal isn’t simply to cut costs, but to ensure that the right patient receives the right therapy at the right time and in the most sustainable setting.” Pharmacy Leadership Representative, Asembia Specialty Pharmacy Summit
The Role of Pharmacy Purchasing Organizations
Collaboration through organizations like Asembia allows health systems to aggregate their purchasing power. By leveraging collective volume, systems can negotiate better pricing and gain access to market intelligence that would be unavailable to a single institution. These partnerships are essential for managing the volatility of the specialty drug market.
Key Takeaways for Health Systems
- Prioritize Site-of-Care: Move infusions and injections to home or clinic settings where possible.
- Integrate Pharmacists: Embed clinical pharmacists in care teams to optimize therapy selection.
- Focus on Adherence: Use data to ensure patients stay on therapy, reducing the risk of costly relapses.
- Collaborate: Use group purchasing organizations to increase negotiating leverage with manufacturers.
Frequently Asked Questions
What exactly is a specialty pharmacy?
A specialty pharmacy handles high-cost, high-complexity medications that require special handling (such as refrigeration), intensive patient monitoring, and comprehensive clinical support.
Why are specialty drugs so much more expensive than traditional meds?
These drugs often involve complex manufacturing processes, such as recombinant DNA technology or live cell cultivation, and are frequently developed for very small patient populations (orphan diseases), which limits the ability to scale costs.
How does site-of-care optimization assist the patient?
It typically reduces the patient’s out-of-pocket costs through lower co-pays and eliminates the stress of visiting a large hospital facility for routine injections.
Looking Ahead
The trajectory of specialty drug spending is unlikely to flatten. However, the shift toward value-based pharmacy
—where payment is tied to patient outcomes rather than the volume of drugs dispensed—offers a path forward. As health systems continue to refine their integrated models, the focus will move beyond the cost of the pill to the total cost of the cure.